PTO/SB/05 03-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY
PATENT APPLICATION
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.		t No.	DX06023US01	
First Inventor Danie		Danie	el J. CUA	
Title	Uses of Mammalian Cytokine; Related Reagents			

APPLICATION ELEMENTS  See MPEP chapter 600 concerning utility patent application contents.  1. X Fee Transmittal Form (e.g., PTO/SB/17) (submit an eiginal and a displeate for fee precessing) 2. Applicant claims small entity status. See 37 CFR 1.27. 3. X Specification [Total Pages_57_] (preferred annapament set forth below) 4. Descriptive title of the invention of the formation of the formation of the invention of the formation of the disclosure of the prior of the formation of the scoremaniation of the formation of the formation of the formation of the formatio	<del>-</del>	Express Mail Laber No.   EL 902 031 117 US					
Computer Program (Appendix)  Applicant claims small entity status. See 37 CFR 1.27.  3. X Specification Cross Reference to Related Applications Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, or a computer program listing appendix Background of the invention Brief Sumary of the Invention Brief Sumary of the Invention Detailed Description of the Drawings (if filed) Claim(s) Abstract of the Disclosure Drawing(s) (33 U.S.C. 113) [Total Pages		ADDRESS TO: Commissioner for Patents P.O. Box 1450					
- Background of the invention - Brief Sumary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure - Abstract of the Disclosure - Mining (s) - Abstract of the Disclosure - Copy from a prior application (37 CFR 1.63(d)) - Copy from a prior application (37 CFR 1.63(d)) - Copy from a prior application (37 CFR 1.63(d)) - DELETION OF INVENTOR(S) - Signed statement attached deleting inventor(s) - named in the prior application, see 37 CFR - 1.63(d)(2) and 1.33(b).  - Application Data Sheet. See 37 CFR 1.76  - Continuation Data Sheet. See 37 CFR 1.76: - Continuation Data Sheet Shee	(submit an original and a duplicate for fee processing)  2. Applicant claims small entity status. See 37 CFR 1.27.  3. X Specification [Total Pages_57] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a	7 CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i CD-ROM or CD-R (2 copies); or  ii paper  c Statements verifying identity of above copies					
i	- Brief Sumary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure  4 Drawing(s) (35 U.S.C. 113) [Total Pages]  5. Oath or Declaration [Total Pages_4] a New executed (original or copy) b Copy from a prior application (37 CFR 1.63(d))	9 Assignment Papers (cover sheet & document(s)) 10 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney 11 English Translation Document (if applicable) 12 Information Disclosure Copies of ID Statement (IDS)/PTO-1449 Citations 13 Preliminary Amendment 14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)					
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) of prior application No.: Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  19. CORRESPONDENCE ADDRESS  X Customer Number or Bar Code Label or Correspondence address below:  DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304 Telephone: (650) 496-6400	i. <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	(if foreign priority is claimed)  16 Nonpublication Request under 35 U.S.C.  122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.					
X Customer Number or Bar Code Label  Or Correspondence address below:  DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304 Telephone: (650) 496-6400	18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) of prior application No.: Fror application information: Examiner: Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b. is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.						
DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304 Telephone: (650) 496-6400							
		DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304 Telephone: (650) 496-6400					

Name (Print/Type)	Tom Brody, Reg. No. 46,433		
Signature	Am, Brody	Date	Feb. 7, 2004
"Everges Mailing" m	ailing Johal number EL 082 851 11/7 LIS	Date of Deposit: February 4, 20	04

"Express Mailing" mailing fabel number <u>EL 982 851 117 US</u> Date of Deposit: <u>February 4, 2004</u>
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. Department of Commerce

Under the Paperwork Reduction Act of	1995, no persons are requi	Complete if Known			
FEE TRANSM	MIIIAL	Application Number			
S for TV 2	304	Filing Date	February 4, 2004		
FEE TRANSMITTAL for FY 2004		First Named Inventor	Daniel J. CUA		
Effective 10/01/2003. Patent fees are subject to annual revision.		Examiner Name			
☐ Applicant claims small entity status. See 37 CFR 1.27		Art Unit			
TOTAL AMOUNT OF PAYMENT (\$) 0		Attorney Docket No.	DX06023US01		

Check Credit Card Other None  X Deposit Account:  Deposit Account Number: 04-1239  3. ADDITIONAL FEES  Large Entity Small Entity Fee Description Fee Paid  Fee Fee Fee Fee Fee Fee Fee Fee Fee Fe	
Deposit Account Number: 04-1239 Fee Fee Fee	
Debosit Account Number. 07-1200	
Densit Assess News DNAY Possarch Inc. Code (\$)	
The Commissioner is authorized to: (check all that apply)  1051 130 2051 65 Surcharge – late filing fee or oath  1052 50 2052 25 Surcharge – late provisional filing fee or	_
Charge fee(s) indicated below _X_ Credit any overpayments cover sheet	_
X Charge any additional fee(s) during the pendency of this	
application	_
X Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	
FEE CALCULATION Examiner action	
1. BASIC FILING FEE  1805 1,840* 1805 1,840*Requesting publication of SIR after	
Examiner action	-
1251 TTO 2251 55 Extension for reply within his month.	-
Code (\$) Code (\$)	-
1253 950 2253 475 Extension for reply within third month  1001 770 2001 385 Utility filing fee0_ 1254 1,480 2254 740 Extension for reply within fourth month	-
1002 340 2002 170 Design filing fee 1255 2,010 2255 1,005 Extension for reply within fifth month	-
1003 530 2003 265 Plant filing fee 1401 330 2401 165 Notice of Appeal	_
1004 770 2004 385 Reissue filing fee 1402 330 2402 165 Filing a brief in support of an appeal	_
1005 160 2005 80 Provisional filing fee 1403 290 2403 145 Request for oral hearing	
SUBTOTAL (1) \$ 0 1451 1,510 Petition to institute a public use proceeding	
1452 110 2452 55 Petition to revive – unavoidable	_
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1453 1,330 2453 665 Petition to revive – unintentional	_
Fee from 1501 1,330 2501 665 Utility issue fee (or reissue)	_
Total Claims 20 20** = 0 Y = 1502 480 2502 240 Design issue fee	_
1503 640 2503 320 Plant issue lee	
Claims 1460 130 Peditions to the Commissioner	
Multiple Dependent = 1807 50 1807 50 Processing fee under 37 CFR 1.17(q)	-
Large Entity Small Entity 1806 180 1806 180 Submission of Information Disclosure Stmt	_
Fee Fee Fee Fee Description 8021 40 Recording each patent assignment per property (times number of properties)	
Code (\$) Code (\$)	-
1202 10 2202 0 Claims in excess of 20	
1201 86 2201 43 Independent claims in excess of 3 (37 CFR 1.129(a)) — 1203 290 2203 145 Multiple dependent claim, if not paid 1810 770 2810 385 For each additional invention to be	-
1204 86 2204 43 ** Reissue independent claims examined (37 CFR 1.129(b))	
over original patent 1801 770 2801 385 Request for Continued Examination (RCE)	_
1205 18 2205 9 ** Reissue claims in excess of 20 1802 900 1802 900 Request for expedited examination	_
and over original patent of a design application	
SUBTOTAL (2) \$ 0 Other fee (specify)	_
** or number previously paid, if greater; For Reissues, see above	

SUBMITTED BY			(Complete (if applicable))				
Name (Print/Type)	Jom Brody	Registration No. 46,433 Telephone 1-650-496-6400			96-6400		
Signature (	The Brody				Date	Fe6,4	, 200A
<del></del>	-/	<del></del>		444 44 44 44 44			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No: DX06023US01

## PATENT APPLICATION

## USES OF MAMMALIAN CYTOKINE; RELATED REAGENTS

## **INVENTORS:**

- Daniel J. Cua, a citizen of the United States, residing at 17418 Bear Creek Road, Boulder Creek, California 95006;
- Yi Chen, a citizen of the United States, residing at 2510 West Middlefield Road, Mountain View, California 94043;
- Robert A. Kastelein, a citizen of the Netherlands, residing at 463 Summit Drive, Redwood City, California 94062;
- Claire L. Langrish, a citizen of the United Kingdom, residing at 1201 Clark Way, Palo Alto, California 94304;
- Donna M. Rennick, a citizen of the United States, residing at 740 Vista Grande, Los Altos, California 94024; and
- Jonathon Sedgwick, a citizen of Australia, residing at 365 North California Avenue, Palo Alto, California 94301.

"Express Mailing" mailing label number EL 982 851 117 US

Date of Deposit February 4, 2004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450.

Customer Number 028008

DNAX Research, Inc. 901 California Avenue

Palo Alto, California 94304-1104

Tel: (650)496-6400 Fax: (650)496-1200